Back to Results

Zeo ScientifiX Inc (ZEOX)

Zeo ScientifiX Inc (ZEOX) is a common stock listing on OTC Markets associated with Zeo ScientifiX, Inc., a healthcare company focused on biotechnology. The company is clinical-stage and works on biological therapeutics aimed at degenerative diseases and regenerative medicine. Its lead candidate, Zofin, is an acellular biologic derived from perinatal sources and is being studied in Phase I/II trials for conditions including COVID-19, chronic obstructive pulmonary disease, osteoarthritis, and traumatic brain injury. Zeo ScientifiX also develops Patient Pure X, an autologous biologic intended to support tissue healing and reduce inflammation, along with topical aesthetic products such as ZEO GROWX, ZEO HAIR GROW, and ZEO GROW BOOST. The company maintains a strategic collaboration with Regen Therapy Limited and was incorporated in 2011. It is based in Davie, Florida, and formerly operated under the name Organicell Regenerative Medicine, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-ZEOX
$1.75
-3.1% Downside
Fair
—
—
—
Fair
—
—
—
0.0%
September 13, 2026
-3.6x
19.8x
2.0x
14.107 M
12.604 M
2.4%
56.7%
-23.8
—
34.8%
Valuation • Fair Value

Zeo ScientifiX Inc (OTC-ZEOX) Fair Value by Valuation Model

Compare the primary fair value estimate for Zeo ScientifiX Inc (OTC-ZEOX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.75

Estimated downside of 3.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.56

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.93

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Zeo ScientifiX Inc (OTC-ZEOX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Zeo ScientifiX Inc (OTC-ZEOX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

6.987 M

Current operating scale indicator.

Revenue Forecast

5.589 M

Forward revenue estimate.

EBITDA

-4.052 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Zeo ScientifiX Inc (OTC-ZEOX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Zeo ScientifiX Inc (OTC-ZEOX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

1,000.00

Higher caution zone on this screen.

Altman Z-Score

-23.8

Lower score that deserves closer risk review.

FCF / Net Income

34.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Zeo ScientifiX Inc (OTC-ZEOX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Zeo ScientifiX Inc (OTC-ZEOX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 13, 2026

Days to Earnings

54

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Zeo ScientifiX Inc (OTC-ZEOX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Zeo ScientifiX Inc (OTC-ZEOX) Stock Forecast & Technical Outlook

Review Zeo ScientifiX Inc (OTC-ZEOX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Zeo ScientifiX Inc (OTC-ZEOX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Zeo ScientifiX Inc (OTC-ZEOX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Zeo ScientifiX Inc (OTC-ZEOX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Zeo ScientifiX Inc (OTC-ZEOX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Zeo ScientifiX Inc (OTC-ZEOX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Zeo ScientifiX Inc (OTC-ZEOX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Zeo ScientifiX Inc (OTC-ZEOX) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Zeo ScientifiX Inc (OTC-ZEOX) Stock FAQ

Quick answers about Zeo ScientifiX Inc (OTC-ZEOX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.75
Estimated downside 3.1%
Valuation Rating
Overvalued
Estimated downside of 3.1%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Zeo ScientifiX Inc (OTC-ZEOX) is $1.75. This implies an estimated downside of 3.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 3.1% versus the current market price.

An analyst price target for Zeo ScientifiX Inc (OTC-ZEOX) is not currently available in the latest data file.

The current financial health read for Zeo ScientifiX Inc (OTC-ZEOX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Zeo ScientifiX Inc (OTC-ZEOX) is September 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Zeo ScientifiX Inc (OTC-ZEOX) is -3.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Zeo ScientifiX Inc is 14.107 M.

The current enterprise value listed for Zeo ScientifiX Inc is 12.604 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Zeo ScientifiX Inc is OTC-ZEOX, and the stock is listed on OTC Markets.

Zeo ScientifiX Inc (OTC-ZEOX) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Zeo ScientifiX Inc is 2.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Zeo ScientifiX Inc is 56.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)